Trevi Therapeutics, Inc. (TRVI)
| Market Cap | 70.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.75M |
| Shares Out | 63.86M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 404,392 |
| Open | 1.11 |
| Previous Close | 1.13 |
| Day's Range | 1.10 - 1.15 |
| 52-Week Range | 0.97 - 3.50 |
| Beta | 0.80 |
| Analysts | Strong Buy |
| Price Target | 6.75 (+508.11%) |
| Earnings Date | Nov 9, 2023 |
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize product... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price forecast is $6.75, which is an increase of 508.11% from the latest price.
News
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
Initiated Phase 2a RIVER trial of Haduvio in refractory chronic cough (RCC) patients and expect topline data in the second half of 2024 Expect to initiate Phase 2b dose-ranging trial of Haduvio for th...
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough
Expect to enroll 60 subjects across a broad range of cough frequencies RIVER topline data expected in the second half of 2024 NEW HAVEN, Conn. , Nov. 2, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (...
Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023
Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis
Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatment Safety data over 52 weeks: treatment was well tolerated and consistent with 14-week bl...
Trevi Therapeutics to Participate in Upcoming September Events
NEW HAVEN, Conn. , Sept. 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER...
Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update
Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2 CANAL trial of chronic cough in patients with idiopathic pulmonary fibrosis ...
Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023
Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Upcoming August Events
NEW HAVEN, Conn. , Aug. 1, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)...
Trevi Therapeutics to Participate in Upcoming July Investor Events
NEW HAVEN, Conn. , July 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)...
Trevi Therapeutics to Participate in Upcoming June Conferences
Dr. Toby Maher will be presenting data results from the Phase 2 CANAL trial in IPF chronic cough at American Cough Conference NEW HAVEN, Conn. , May 30, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (...
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence
Nalbuphine ER resulted in a rapid and marked reduction in recorded daytime cough among patients suffering from IPF-related cough The mean change in 24-hour objective cough frequency was similar in pat...
Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
I nitiating three clinical studies in chronic cough indications later this year Received Notice of Allowance for key U.S. patent for the use of oral nalbuphine ER for the treatment of chronic cough in...
Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023
Presentation to take place on June 1 from 10:30 a.m. to 12:00 p.m.
Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023
Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.
Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference
Dr. Toby Maher of the Keck School of Medicine will give oral presentations for both scientific abstracts on oral nalbuphine extended release for chronic cough in IPF NEW HAVEN, Conn. , May 2, 2023 /PR...
Trevi Therapeutics to Participate in Upcoming May Investor Events
2023 Aegis Virtual Conference, May 2-4 American Thoracic Society's (ATS) 2023 Respiratory Innovation Summit (RIS), May 19-20 Yale Innovation Summit, May 31-June 1 NEW HAVEN, Conn. , April 27, 2023 /PR...
Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults wi...
Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
Multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. EDT NEW HAVEN, Conn.
Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023
Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.
Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
NEW HAVEN, Conn. , March 8, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER...
Trevi Therapeutics to Participate in Upcoming March Conferences
Frazier/Fenwick Winter Investor Event, March 7-10 Oppenheimer 33rd Annual Healthcare Conference, March 13-15 – Corporate presentation will be held on Monday, March 13, at 4:00 p.m. ET BIO-Europe Sprin...
Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023
Corporate presentation at 10:50 a.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Present and Participate in Upcoming February Conferences
BIO CEO & Investor Conference, February 6-9 – Corporate presentation Tuesday, February 7, at 10:45 a.m. ET SVB Securities Global Biopharma Conference, February 13-16 – Corporate presentation Tuesday, ...
Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 25, 2023) - The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (NASDAQ: TRVI) ("the Company"), a clinical-stage biopharmaceutical company developing th...
Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences
NEW HAVEN, Conn. , Jan. 5, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)...